Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) is among the 12 Best Performing Stocks in February.

On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)'s price objective to $12 from $7, maintaining an Overweight rating. The firm pointed out ANKTIVA's strong commercial momentum, reporting U.S. net revenues of approximately $113 million in 2025, noting a roughly 700% increase. Piper Sandler now forecasts ANKTIVA revenue of $195 million in 2026, showing that demand for the company's immunotherapy treatment remains strong.

On February 26, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) concluded enrollment in the Phase 2 QUILT 2.005 randomized study, which compared ANKTIVA + Bacillus Calmette-Guérin (BCG) to BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer carcinoma in situ. The trial enrolled 366 patients and randomly assigned them to the two therapy groups ahead of schedule. An interim review conducted by the US Food and Drug Administration found that the combined therapy increased the durability of complete response, with 85% of patients retaining response at six months compared to 57% for BCG alone, and 84% at nine months versus 52%. The firm plans to submit a biologics licensing application in the fourth quarter of 2026.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy business. It creates next-generation treatments that activate immunogenic pathways to combat cancer and infectious diseases.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.